Status:
COMPLETED
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
Lead Sponsor:
Pfizer
Conditions:
Hepatic Insufficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
Eligibility Criteria
Inclusion
- Diagnosis of reduced hepatic function (Child Pugh Classification A or B)
- Body Mass Index of 18-32 kg/m2
Exclusion
- History of febrile illness within 5 days prior to first dose
- Any condition possibly affecting drug absorption (e.g. gastrectomy)
- Positive urine drug screen
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00692341
Start Date
May 1 2008
End Date
October 1 2008
Last Update
April 11 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Miami, Florida, United States, 33169
2
Pfizer Investigational Site
Orlando, Florida, United States, 32809